Evaluation of a tumor informed MRD assay with contrived breast cancer samples Read more about Evaluation of a tumor informed MRD assay with contrived breast cancer samples
ctDNA dynamics in early stage node negative non-small cell lung cancers Read more about ctDNA dynamics in early stage node negative non-small cell lung cancers
Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence Read more about Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence
Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay Read more about Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay
Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay Read more about Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay
Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies Read more about Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies
Spatial Analysis of Genomic Signatures on Colorectal Cancer Pathogenesis Using the NanoString GeoMx® Digital Spatial Profiler Read more about Spatial Analysis of Genomic Signatures on Colorectal Cancer Pathogenesis Using the NanoString GeoMx® Digital Spatial Profiler
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer Read more about Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Read more about Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD) Read more about A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)